ESMO Breast 2020: will you be among the contributors to the latest data in breast cancer? Submit your abstract by 4 February 2020
There are many good reasons to become an ESMO member. Find out why you should join Europe's leading medical oncology society
Our journals offer ESMO members and the oncology community a globally visible platform to publish scientific studies, and a highly credible source of educational updates.
The ESMO-MCBS scale is a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Giuseppe Curigliano, ESMO Breast Cancer Co-Chair, shares his thoughts about the upcoming edition of the Congress and the reasons why oncologists should ensure they present their new data at this meeting.
12 Dec 2019
Webcasts, slides and abstracts are available online!
12 Dec 2019
Two studies describe impact of the initiation of steroids early during the course of immune checkpoint inhibition on patient outcome
12 Dec 2019
Nivolumab plus ipilimumab is effective regardless of PD-L1 expression levels in advanced NSCLC
12 Dec 2019
Efficacy of pembrolizumab alone or combined with chemotherapy is solid regardless of KRAS mutations in non-squamous non-small cell lung cancer
11 Dec 2019
The results from the ALCYONE study
10 Dec 2019
Abstracts are available on OncologyPRO
Geneva, Switzerland
11 Dec
- 14 Dec
2019
Milan, Italy
03 Feb
- 05 Feb
2020
Cape Town, South Africa
13 Feb
- 14 Feb
2020
Cape Town, South Africa
14 Feb
- 16 Feb
2020
Mumbai, India
28 Feb
- 01 Mar
2020
Paris, France
02 Mar
- 04 Mar
2020
